Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Gain Therapeutics Inc(GANX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GANX
09/25/2026: GANX (1-star) is currently NOT-A-BUY. Pass it for now.
Gain Therapeutics is a clinical-stage biotechnology firm dedicated to creating small-molecule treatments for lysosomal and protein-misfolding diseases. The company's main strength is its proprietary SEE-Tx platform, which enables the discovery of novel therapeutic binding sites. Its primary growth opportunity lies in moving lead candidates like GT-02287 through clinical trials to potential commercialization or strategic licensing. However, the company faces significant risks, including the inherent uncertainty of clinical development, a lack of current revenue, and the need for ongoing capital raises. This stock is best suited for risk-tolerant investors seeking exposure to drug discovery; investors should monitor clinical milestones and potential partnership announcements closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high growth potential linked to R&D milestones, but carries the extreme risk of clinical-stage biotech. |
| Momentum investor | Mixed fit | Momentum may occur around clinical data releases, but the stock lacks the consistent trend history required for long-term momentum strategies. |
| Value investor | Weak fit | As a non-profitable, early-stage biotech firm, traditional valuation metrics are not applicable. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital. |
| Low-risk investor | Weak fit | The high volatility and clinical success risks are unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can cause significant, rapid share price fluctuations. |
| Valuation risk | High | Speculative valuations based on future outcomes present significant downside if milestones are missed. |
| Competition risk (rare disease therapeutics) | High | Larger, better-capitalized competitors can out-invest and out-market smaller biotech firms. |
| Business quality | Medium | The company is early-stage without a commercial franchise or proven revenue stream. |
| Dividend income | Low / none | Investors should expect no income, only speculative capital gain. |
| Execution risk | High | The complexity of drug development and regulatory approval poses significant operational hurdles. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -54.85% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 77.69M USD | Price to earnings Ratio - | 1Y Target Price 7.2 |
Price to earnings Ratio - | 1Y Target Price 7.2 | ||
Volume (30-day avg) 364.5K shares | Beta 0.21 | 52 Weeks Range 1.53 - 4.34 | Updated Date 09/27/2026 |
52 Weeks Range 1.53 - 4.34 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.5 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Drug Development | Research, development, and eventual licensing of small-molecule therapeutics for rare diseases. | The company burns cash to create drugs; revenue will only arrive through future drug sales or licensing deals. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 68.05M | Price to Sales(TTM) 255.5 |
Enterprise Value 68.05M | Price to Sales(TTM) 255.5 | ||
Enterprise Value to Revenue 138.33 | Enterprise Value to EBITDA -1.55 | Shares Outstanding 43.64M | Shares Floating 42.64M |
Shares Outstanding 43.64M | Shares Floating 42.64M | ||
Percent Insiders 2.23 | Percent Institutions 19.87 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Gain Therapeutics Inc
Exchange NASDAQ | Headquarters Bethesda, MD, United States | ||
IPO Launch date 2021-03-18 | President, CEO & Director Mr. Gene Mack M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://gaintherapeutics.com |
Full time employees 20 | Website https://gaintherapeutics.com | ||
Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.